Table 5C.
Strong RBD-IgG antibody decline for dialysis patients (n = 908).
| Risk factor | OR | 95% CI | p-value |
|---|---|---|---|
| Age | 1·009 | [0·999,1·019] | 0·087 |
| Sex (Ref. = female) | 1·441 | [1·081,1·922] | 0·013 |
| Vaccine type (Ref. = mRNA-1273) | 2·592 | [1·621,4·143] | <0·001 |
| BMI | 0·983 | [0·959,1·008] | 0·188 |
| IS drugs (Ref. = no drugs) | 0·894 | [0·398,2·008] | 0·787 |
| Time on dialysis | 0·961 | [0·937,0·986] | 0·003 |
| Hep B vacc failure | 1·185 | [0·846,1·659] | 0·323 |
| Diabetes mellitus (Ref. = none) | 1·251 | [0·934,1·676] | 0·134 |
Ref. = reference category; a “strong RBD-IgG antibody decline” ” between T2 (two months after first vaccination) and T3 (six months) was defined as described in Results and in more detail in Supplementary material. Comparator is the MP cohort. IS means immunosuppressive; BMI means body mass index; Hep B vacc failure definition - patients with unsuccessful vaccination after at least four attempts.
Model fit: AIC = 1211.87; BIC = 1259.81